192 related articles for article (PubMed ID: 25629161)
41. A prime/boost vaccination with HA DNA and Pichia-produced HA protein elicits a strong humoral response in chickens against H5N1.
Stachyra A; Pietrzak M; Macioła A; Protasiuk A; Olszewska M; Śmietanka K; Minta Z; Góra-Sochacka A; Kopera E; Sirko A
Virus Res; 2017 Mar; 232():41-47. PubMed ID: 28159612
[TBL] [Abstract][Full Text] [Related]
42. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
43. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
44. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.
Wang G; Zhou F; Buchy P; Zuo T; Hu H; Liu J; Song Y; Ding H; Tsai C; Chen Z; Zhang L; Deubel V; Zhou P
J Infect Dis; 2014 Mar; 209(5):676-85. PubMed ID: 23911711
[TBL] [Abstract][Full Text] [Related]
45. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.
Schwartz JA; Buonocore L; Suguitan A; Hunter M; Marx PA; Subbarao K; Rose JK
J Virol; 2011 May; 85(9):4602-5. PubMed ID: 21325423
[TBL] [Abstract][Full Text] [Related]
46. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
47. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.
Höschler K; Gopal R; Andrews N; Saville M; Pepin S; Wood J; Zambon MC
Influenza Other Respir Viruses; 2007; 1(5-6):199-206. PubMed ID: 19453427
[TBL] [Abstract][Full Text] [Related]
48. Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.
Prabakaran M; Leyrer S; He F; Auer S; Kumar SR; Kindsmueller K; Mytle N; Schneider J; Lockhart S; Kwang J
PLoS One; 2014; 9(9):e107316. PubMed ID: 25229722
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
Pantin-Jackwood MJ; Kapczynski DR; DeJesus E; Costa-Hurtado M; Dauphin G; Tripodi A; Dunn JR; Swayne DE
Avian Dis; 2016 Mar; 60(1):22-32. PubMed ID: 26953940
[TBL] [Abstract][Full Text] [Related]
50. Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.
Swayne DE; Suarez DL; Spackman E; Jadhao S; Dauphin G; Kim-Torchetti M; McGrane J; Weaver J; Daniels P; Wong F; Selleck P; Wiyono A; Indriani R; Yupiana Y; Sawitri Siregar E; Prajitno T; Smith D; Fouchier R
J Virol; 2015 Apr; 89(7):3746-62. PubMed ID: 25609805
[TBL] [Abstract][Full Text] [Related]
51. Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection.
Zou Z; Hu Y; Liu Z; Zhong W; Cao H; Chen H; Jin M
Vet Res; 2015 Apr; 46(1):42. PubMed ID: 25889564
[TBL] [Abstract][Full Text] [Related]
52. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus.
Niqueux E; Guionie O; Amelot M; Jestin V
Vaccine; 2013 Aug; 31(38):4121-8. PubMed ID: 23845804
[TBL] [Abstract][Full Text] [Related]
53. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
55. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.
Du L; Zhao G; Sun S; Zhang X; Zhou X; Guo Y; Li Y; Zhou Y; Jiang S
PLoS One; 2013; 8(1):e53568. PubMed ID: 23320093
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
58. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
59. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
60. Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.
Levine MZ; Holiday C; Liu F; Jefferson S; Gillis E; Bellamy AR; Tumpey T; Katz JM
J Infect Dis; 2017 Sep; 216(suppl_4):S555-S559. PubMed ID: 28934456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
